Expert Statement: Tom Wilson, Pfizer
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Topics
Expert Statement: Rohtash Kumar, Veranova
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Federico Pollano, Rentschler
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Prasad Raje, LGM Pharma
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Gordon Bates, Lonza
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Ludwig de Mot, EuroAPI
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Kenneth N. Drew, Flamma
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Russel Miller, Enzene
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Frank Wegener, ESIM Chemicals
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: David McErlane and Aris Gennadios, Catalent
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Ashu Tandon, Aragen
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Tom Sellig, Adare Pharma Solutions
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Gavin Murdoch, Abzena
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Using Chemistry to Create Net-Zero Value Chains
In this interview, Charlie Tan, CEO of the Global Impact Coalition (GIC), explains the initiative’s scope and describes some key activities.
Productivity in Biopharma Research Picks Up
Technological developments in the pharmaceutical and biotech industry are reflected in increased funding, higher R&D productivity and more product launches. However, the general conditions remain challenging. Incremental change won’t be enough to deliver the results that the market and patients demand, warn industry experts.
Formulating Innovative Concepts
Matthias Hofmann, Group Innovation & Technology Management Director at Azelis, provides an in-depth insight into the company’s innovation activities and the underlying market trends.
Innovation Through Formulation
Anna Bertona, Group CEO at Azelis, looks back on her first six month in this role and gives an insight into her plans for the company's development.
Sustainable Material Adoption in Industrial Sectors
IMCD Industrial Solutions surveyed top customers around the globe on their insights into eight key topics deemed pertinent to sustainability in industrial sectors. This article highlights some of the most important results.
Positioned for Growth: The New Age of Winning for Chemical Distributors
The 2023 chemical distribution survey shows recent trends and evolving principals’ expectations.
Elixir Group Continues Sustainable Growth Strategy
The Serbian Elixir Group continues to focus clearly on expansion and sustainability.
Unleashing CDMO Growth through Effective Pricing
In the rapidly evolving industry of contract development and manufacturing organizations (CDMOs), a well-defined pricing strategy is essential to drive growth and profitability. To stay ahead and participate in the expansion of the market, CDMOs need to transition to a structured value-based pricing approach that considers customer value, complexity, and specific needs.
The Green Power of Catalysis
With more than 80% of all chemical products manufactured using catalytic processes, catalysts are the number one value generator in the chemical industry.
Packaging Industry Drives Circular Economy through Science, Innovation and Consumer Insights
The concept of a circular economy, where materials are recycled and reused, is becoming increasingly important in consumer packaging, driven by regulatory requirements and customer interest.
Spray Drying for Inhalation: the Challenges of Scale-up
When developing an inhaled powder formulation, the drug particles’ properties are critical to successful delivery to the deep lung. The aerodynamic diameter is the key parameter, as it represents how well the particle flies in an air stream.
The Use of Evonik’s Catalysts to Manufacture TFA-free Margarines
When manufacturing specialty edible fats, ensuring that the product has the desired properties – such as a stable shelf life, optimal melting behavior, and texture – is essential.
Providing Solutions by Making the Most of Biomedical Data
Many life science companies generate large swathes of data.
How CDMOs Can Contribute to Pharma Supply even Better
The demand for medicines is increasing rapidly and R&D pipelines have doubled over the last decade.
The Success Story of Biosimilars
With their triumphant advance, biosimilars are also setting in motion the usual market mechanisms. Biopharma interest groups warn against the automatic substitution of originator drugs.
New Biologics and Advanced Therapies
The pharmaceutical market is undergoing a profound transformation, driven by innovation among biologics and advanced therapies (ATs). This shift is not only redefining the treatment landscape but also presenting new opportunities and challenges related to the drug development and manufacturing value chain.
The Evolution of CDMOs
Contract development and manufacturing organizations (CDMOs) are a crucial part of the life sciences industry. Strangely, despite its current prominence, the CDMO industry is a relatively young one. There have been significant developments over its short lifespan, and it is likely that we see even more growth in the years to come.
European Chemicals Pulse Check
In its latest European Chemicals Pulse Check, Deloitte surveyed senior executives in the European chemical industry and industry associations about their views on current market challenges, trends and opportunities.
Rising Chinese Investments in New Chemical Segments
China’s chemical industry originally focused primarily on basic chemicals, in line with the domestic needs of a developing economy and the lower technology requirements for the production of these materials. By now, China dominates the global market for many such chemicals – for example, the country accounts for about 55% of the global capacity for acetic acid, about 50% of the global carbon black capacity and about 45% of the global capacity for titanium dioxide. For many such commodity chemicals, China started out as a net importer, then built up domestic capacity and ended up being a major exporter.
A Journey towards the Smart Factory
Achieving sustainability targets and productivity improvements are primary levers that make operations teams successful. At MBCC Group, one of the leading construction chemicals players, Wayne Towell, Vice President of Operations has been driving various initiatives to track, monitor and enhance productivity of their plants across the globe.
Creating added value through innovation and transformation
As a global specialty chemicals company, Altana develops innovative technologies, solutions, and products with a clear customer focus. The company aims to strengthen and expand this position in the long term. The topic of digital transformation plays a key role.
Creating added value through innovation and transformation
As a global specialty chemicals company, Altana develops innovative technologies, solutions, and products with a clear customer focus. The company aims to strengthen and expand this position in the long term. The topic of digital transformation plays a key role.
